Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
about
Emerging and future therapies for hemophiliaModulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.Half-life extended biotherapeutics.Implementation of a recombinant factor IX Fc fusion protein extended-infusion desensitization protocol.In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
P2860
Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Alprolix (recombinant Factor I ...... and treatment of hemophilia B.
@en
Alprolix
@nl
type
label
Alprolix (recombinant Factor I ...... and treatment of hemophilia B.
@en
Alprolix
@nl
prefLabel
Alprolix (recombinant Factor I ...... and treatment of hemophilia B.
@en
Alprolix
@nl
P2093
P2860
P921
P1476
Alprolix (recombinant Factor I ...... and treatment of hemophilia B.
@en
P2093
Jerry S Powell
Jonathan M Ducore
Maricel G Miguelino
P2860
P304
P356
10.1586/17474086.2014.951322
P577
2014-08-21T00:00:00Z